Enzymatica AB (publ) (STO:ENZY)

Market Cap	825.30M
Revenue (ttm)	45.58M
Net Income (ttm)	-53.18M
Shares Out	242.74M
EPS (ttm)	-0.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,694
Average Volume	127,525
Open	3.450
Previous Close	3.400
Day's Range	3.340 - 3.530
52-Week Range	1.340 - 5.450
Beta	0.39
RSI	46.91
Earnings Date	Apr 10, 2025

About Enzymatica AB

Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The company’s product includes ColdZyme, a mouth spray to treat and alleviate cold and flu symptoms. It also provides enzyme formulations for skin care. The company offers its products through contract organizations and partner agreements with distributors who sell the products under the ViruProtect, STADAProtect, and Bisolviral brand names. Enzymatica AB (publ) was incorporated in 2007 and i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ENZY

Financial Performance

In 2024, Enzymatica AB's revenue was 45.58 million, a decrease of -10.47% compared to the previous year's 50.90 million. Losses were -53.18 million, 6.94% more than in 2023.